Published on in CHOP News
CHOP researchers found that a series of “liquid biopsies” could less invasively and more accurately identify tumor changes in patients with high-risk neuroblastoma.
Published on in CHOP News
Researchers from Children’s Hospital of Philadelphia (CHOP) have found that economically disadvantaged children treated with CAR T-cell therapy for relapsed/refractory acute lymphoblastic leukemia (ALL) fair just as well as children from more socioeconomically advantaged backgrounds.
Published on in CHOP News
CHOP researchers have identified a protein on the surface of multiple pediatric brain tumors that they can target using immunotherapy in preclinical models.
Published on in CHOP News
Presenting Sponsor Citadel Credit Union Doubled Pledge and Renewed its Partnership for Annual Event Aimed at Conquering Childhood Cancer.
Published on in CHOP News
A new study by a multi-institutional group of pediatric cancer researchers, including those at CHOP, has characterized the genomic landscape for acute lymphoblastic leukemia.
Published on in CHOP News
A leading study site for nearly a decade, CHOP will be part of a network of treatment centers in the country offering the therapy to patients who require regular blood transfusions.
Published on in CHOP News
CHOP has helped launch NCI-backed “Molecular Targets Platform” to streamline and catalyze drug development by harmonizing data about pediatric cancer targets and pathways.
Published on in CHOP News
CHOP played an instrumental role in leading one of two clinical trials that led to the approval of Xalkori® for unresectable, recurrent, or refractory ALK-positive IMT.
Published on in CHOP News
The coalition’s members work to advance a variety of childhood cancer causes by unifying their efforts.
Published on in CHOP News
As a designated PTEN Center of Excellence, CHOP offers the highest standards in multidisciplinary care.